enhances overall well-being. Enliven’s discovery process combines deep insights into clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies. Enliven is based in Burlingame, California. To learn
more, visit www.enliventherapeutics.com and connect with us on LinkedIn and X.
Forward-Looking Statements
This press release contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and
Section 27A of the Securities Act of 1933, as amended) concerning Enliven and other matters that involve substantial risks and uncertainties. These statements may discuss goals, intentions and expectations as to future plans, trends, events,
results of operations and financial condition, or otherwise, based on current beliefs of Enliven’s management, as well as assumptions made by, and information currently available to, Enliven’s management. Forward-looking statements
generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,”
“anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” and other similar expressions or the negative or plural of these words, or other similar
expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. Statements that are not historical facts are forward-looking statements. Forward-looking statements in this
press release include, but are not limited to: statements regarding the potential of, and plans regarding, market opportunities, commercial readiness, potential commercialization, and expectations regarding relcobatinib (ELVN-001); statements regarding the potential differentiated attributes and therapeutic benefit of relcobatinib; the continued conduct, design and future clinical evaluation of relcobatinib, including the planned ENABLE-2 Phase 3 trial and the potential timing of initiation of ENABLE-2; expectations regarding the Company’s growth, transition to late-stage development and
commercialization, and the creation of long-term shareholder value; and statements by Enliven’s Chief Executive Officer and a member of Enliven’s Board of Directors. Forward-looking statements are based on current beliefs and assumptions
that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various risks and uncertainties, including, without
limitation the limited operating history of Enliven; relcobatinib failing to demonstrate sufficient safety, efficacy, tolerability, durability, differentiated attributes or therapeutic benefit in current or future clinical trials; delays or
difficulties in recruiting, enrolling or maintaining patients in relcobatinib clinical trials; the risks of delays in completing the ongoing ENABLE trial or initiating ENABLE-2; Enliven failing to complete the
ongoing ENABLE trial, to initiate ENABLE-2 or to advance relcobatinib through clinical development; regulatory authorities disagreeing with Enliven’s clinical trial design, endpoints or interpretation of
data, or requiring additional studies or diagnostics; developments relating to Enliven’s competitors and industry which may affect the development or potential market opportunity for relcobatinib; and the potential inability of Enliven to
obtain regulatory approval for, or ultimately commercialize or license, relcobatinib or other product candidates; Enliven’s limited resources; Enliven’s limited experience as a company in designing and conducting clinical trials;
Enliven’s lack of commercialization expertise; the ability to attract, hire, and retain highly skilled executive officers and employees; the ability of Enliven to protect its intellectual property and proprietary technologies; the scope of any
patent protection Enliven obtains or the loss of any of Enliven’s patent protection; reliance on third parties, including medical institutions, contract manufacturing organizations, contract research organizations and strategic partners;
geopolitical developments, general market or macroeconomic conditions; Enliven’s ability to obtain additional capital to fund Enliven’s general corporate activities and to fund Enliven’s research and development; and other risks
and uncertainties more fully described in Enliven’s filings with the
